TrimRX Novo Nordisk submits application for FDA approval of CagriSema for weight management CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Buy Cagrilintide 5mg 10mg Third Party Tested BioEdge Peptides